Beijing Med-Pharm Corporation Expands Its Women's Health Portfolio in China Through Agreement with Taiwan Biotech Co., Ltd.

PLYMOUTH MEETING, Pa. -- Beijing Med-Pharm Corporation (BJGP.OB) today announced that it has entered an agreement with Taiwan Biotech Co., Ltd. to serve as the exclusive distributor of ritodrine hydrochloride (trade name Anpo), a treatment for preterm labor, in mainland China. Under the terms of the agreement, Beijing Med-Pharm will also provide sales and marketing support for the product.

"We were pleased to be selected by Taiwan Biotech as their exclusive distribution partner for Anpo," said David Gao, Chief Executive Officer of Beijing Med-Pharm. "Anpo is the recommended treatment for women with threatened preterm labor available in China and is an excellent fit with our growing portfolio of women's health products. With this agreement, we also welcome Taiwan Biotech to the roster of international pharmaceutical companies that have chosen Beijing Med-Pharm as their gateway to mainland China."

"Taiwan Biotech Co., Ltd. is the largest pharmaceutical manufacturer in Taiwan with many products already on the market," said Dr. Jeorge Ko, Chairman of Taiwan Biotech. "With their established distribution network and relationships with major hospitals throughout China, we believe Beijing Med-Pharm will be able to rapidly increase the market share and brand awareness of Anpo. Because the success of Anpo will establish the foundation for exploring additional collaborative opportunities in the future, this agreement has strategic importance for both Companies. We look forward to working closely with Beijing Med-Pharm to forge a strong and long-lasting partnership."

Anpo (ritodrine hydrochloride), a muscle relaxant, has been approved by China's State Food and Drug Administration (SFDA) and was listed in National Reimbursement Drug List in 2004. The reported incidence of preterm labor in China is 7.8 percent although one study suggests that as many as 28.8 percent of pregnant women in China may experience threatened early labor. Beijing Med-Pharm will distribute Anpo in both oral (10 mg tablets) and injectable forms.

About Taiwan Biotech Co., Ltd.

Taiwan Biotech Co., Ltd. was established in 1945 and was the first pharmaceutical company in Taiwan. Over the past 60 years, the Company has evolved to become a leader in the biotech industry, supplying quality products and playing an important role in the development of the pharmaceutical industry in Taiwan. Its steady growth has been fueled for six decades by a deep commitment to product innovation and continuous quality improvement to promote healthy living.

To pursue diversification and globalization, while maintaining a high-tech orientation, Taiwan Biotech Co., Ltd. has moved aggressively to establish a global market presence through international collaborations, strategic alliances, and the introduction and export of proprietary technology.

About Beijing Med-Pharm Corporation

Beijing Med-Pharm is a pharmaceutical marketing and distribution company that offers the following services in China: pre-market entry analysis; clinical trial management; product registration; market research; pharmaceutical distribution to hospitals; and pharmaceutical marketing to physicians, hospitals and other healthcare providers.

Forward Looking Statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the distribution agreement with Taiwan Biotech Co., Ltd. and the market share and brand awareness of Anpo. Forward looking statements provide Beijing Med-Pharm's current expectations or forecasts of future events. Beijing Med-Pharm's results could differ materially from those reflected in the forward-looking statements due to uncertainties relating to the sales potential and the acceptance of Anpo in the Chinese marketplace, changes in Beijing Med-Pharm's sales and marketing strategy, decisions of regulatory authorities, Beijing Med-Pharm's ability to execute its commercial plans, and general financial, economic, regulatory and political conditions affecting the Chinese pharmaceutical industry generally. For a discussion of these and other risks and uncertainties that may affect the forward-looking statements, please see the risk factors included in Beijing Med-Pharm's Annual Report for the year ended December 31, 2005 and Quarterly Report for the quarter ended March 31, 2006, both on file with the Securities and Exchange Commission. Given these risks and uncertainties, the forward-looking statements may prove to be incorrect. Therefore, you should not rely on any forward-looking statements. Beijing Med-Pharm undertakes no obligation to update publicly any forward-looking statements.